Anna Beryozkina on Blogger
PharmD Recipient and Biopharmaceutical Scientist
Tuesday, May 7, 2019
ASCO to Tackle Rural Cancer Care Disparity
An accomplished researcher, Dr. Anna Beryozkina serves as an associate clinical scientist with Genentech in San Francisco, California. In her role, she reviews and analyzes data gathered from clinical trials of drugs used to treat rheumatoid arthritis and cancer. Outside of this work, Dr. Anna Beryozkina belongs to the American Society of Clinical Oncology (ASCO).
Beginning in the fall of 2018, ASCO began exploring ways to address the ongoing cancer care disparity between urban and rural patients. Specifically, those who live in rural areas experience worse outcomes and are diagnosed with cancer at a higher rate than those living in urban settings. To that end, ASCO officially announced the launch of the Rural Cancer Care Task Force in April 2019 to begin the work of finding ways to close these care gaps.
The organization has identified four major pathways the Rural Cancer Care Task Force plans to focus on: provider education/training, workforce recruitment/growth, expansion of telehealth care, and support of relevant research.
In her comments, ASCO President Monica Bertagnolli, MD, FACS, FASCO, acknowledged that a patient’s home location plays a major role in their chance of beating cancer, and changing that is the fundamental work that the task force will address. For more information about the Rural Cancer Care Task Force and other efforts by ASCO to address disparate care, visit asco.org.
Thursday, March 28, 2019
ACR Urges Congress to Set Aside DoD Funds for Arthritis Research
An accomplished research professional, Dr. Anna Beryozkina has focused her career on taking part in the development and testing of new drugs and treatments to battle diseases such as cancer and rheumatoid arthritis. Alongside her research work, Dr. Anna Beryozkina regularly attends annual events of leading professional organizations, including the American College of Rheumatology (ACR).
According to ACR, arthritis is the most common medical condition that leads to disability among veterans in the United States, with one out of every three diagnosed with the condition. In spite of these alarming figures, the Department of Defense (DoD) has yet to earmark any funding to research arthritis and its effects on service members. That’s why ACR is joining with the Arthritis Foundation in calling upon Congress to take action and set aside $20 million of the DoD’s annual budget for arthritis research.
In his comments, retired U.S. Navy Commander and Arthritis Foundation supporter Steve Smith said that the data is overwhelming concerning the disproportionate impact arthritis has on U.S. veterans. He says that it’s long past due that Congress take action on this issue by setting aside this funding, which would be used to study new treatment options and prevention methods.
According to ACR, arthritis is the most common medical condition that leads to disability among veterans in the United States, with one out of every three diagnosed with the condition. In spite of these alarming figures, the Department of Defense (DoD) has yet to earmark any funding to research arthritis and its effects on service members. That’s why ACR is joining with the Arthritis Foundation in calling upon Congress to take action and set aside $20 million of the DoD’s annual budget for arthritis research.
In his comments, retired U.S. Navy Commander and Arthritis Foundation supporter Steve Smith said that the data is overwhelming concerning the disproportionate impact arthritis has on U.S. veterans. He says that it’s long past due that Congress take action on this issue by setting aside this funding, which would be used to study new treatment options and prevention methods.
Tuesday, February 19, 2019
The 2019 EULAR Congress
An associate clinical scientist at Genentech, Anna Beryozkina is responsible for ensuring efficient and effective execution of the Clinical Development Plan (CDP) and developing clinical strategies for addressing assigned molecule(s) and indication(s). To augment her clinical work, Anna Beryozkina maintains membership with the European League Against Rheumatism.
Committed to building a network of professionals dedicated to fighting musculoskeletal and rheumatic diseases, European League Against Rheumatism (EULAR) represents health professionals and patients in all nations across Europe. To this end, EULAR holds the European Congress of Rheumatology, an annual event that will take place from June 12 to 15 in Madrid in 2019.
Registration is now open for the 2019 EULAR Congress. Registration categories span clinical specialties, from scientific and medical professionals to trainees and patients, and prices vary accordingly. Registration includes all of the scientific sessions, networking platforms, and exhibitions at the event, plus several additional benefits, such as unrestricted access to accepted abstracts and one-year access to recordings of the event's presentations. Group registrations are also available. Register by visiting www.congress.eular.org.
Committed to building a network of professionals dedicated to fighting musculoskeletal and rheumatic diseases, European League Against Rheumatism (EULAR) represents health professionals and patients in all nations across Europe. To this end, EULAR holds the European Congress of Rheumatology, an annual event that will take place from June 12 to 15 in Madrid in 2019.
Registration is now open for the 2019 EULAR Congress. Registration categories span clinical specialties, from scientific and medical professionals to trainees and patients, and prices vary accordingly. Registration includes all of the scientific sessions, networking platforms, and exhibitions at the event, plus several additional benefits, such as unrestricted access to accepted abstracts and one-year access to recordings of the event's presentations. Group registrations are also available. Register by visiting www.congress.eular.org.
Subscribe to:
Posts (Atom)